Trastuzumab

'Alarming' underuse of trastuzumab in breast cancer
Nearly one-half of all eligible patients aged 65 years and older with Stage I–III breast cancer do not receive trastuzumab-based therapy, which has been proven effective. In a study published in the Journal of Clinical Oncology, researchers found that ... [...]
2
Like
Save
Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer The …
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced ... [...]
5
Like
Save
Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced ... [...]
3
Like
Save
Drug Duo trastuzumab Shrinks Breast Cancer Tumor In 11 Days
Patients diagnosed with a specific form of breast cancer may have a new treatment option to look out for, as it shows promise in shrinking tumors. The drug duo trastuzumab (Herceptin ®) and lapatinib (Tyverb ®), when used after diagnosis and before ... [...]
2
Like
Save
Combination of lapatinib and trastuzumab shrinks HER2 positive breast cancer …
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according ... [...]
7
Like
Save
Excitement at lapatinib and trastuzumab combination's ground-breaking …
The finding that around a quarter of woman with HER2 positive breast cancer who were treated with lapatinib and trastuzumab saw their tumors shrink or disappear has 'ground-breaking' potential, an expert has said. Women in the clinical trial, who had ... [...]
5
Like
Save
Single Dose of Trastuzumab Kick Starts Immune Response in Certain Breast Cancers
“Our study showed, for the first time, that the immune-cell–activating properties of trastuzumab are likely related to the subtypes of breast cancer,” Varadan said. “Knowing this can inform future trials studying the usefulness of adding immunotherapy ... [...]
1
Like
Save